Advertisement
LLY vs PFE
Which Stock Would AI Choose? Eli Lilly (LLY) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- LLY reported Q2 2026 revenue of $23.0 billion, up 48% year over year, driven primarily by strong demand for its GLP-1 portfolio.
- PFE posted Q2 2026 revenue of $15.03 billion, up 3% year over year, with non-COVID products contributing to operational growth of 5%.
- LLY completed a $3.8 billion acquisition of AtaiBeckley in September 2026 to expand its neuroscience pipeline.
- PFE raised its full-year 2026 revenue guidance midpoint to $61.5 billion while expanding cost-saving targets beyond $10 billion.
- LLY shares have delivered 48% one-year total return, significantly outpacing PFE’s 19% gain over the same period.
- PFE offers a dividend yield above 6%, providing income-focused investors with a higher current yield than LLY.
Introduction
Pharmaceutical giants LLY (Eli Lilly and Company) and PFE (Pfizer Inc.) represent contrasting profiles within the healthcare sector. One company benefits from rapid growth in obesity and diabetes treatments, while the other focuses on stabilizing post-pandemic operations through diversified products and cost discipline. This comparison examines recent performance, business drivers, and market positioning to assist traders and long-term investors evaluating relative opportunities in large-cap pharmaceuticals.
LLY Overview and Recent Performance
Eli Lilly and Company develops and commercializes medicines in diabetes, obesity, oncology, and neuroscience. In recent market activity, LLY shares traded near $1,115, reflecting a one-month decline of approximately 8% amid broader sector rotation, while maintaining a one-year gain of 48%. Strong quarterly results and pipeline momentum supported sentiment. The company completed its $3.8 billion acquisition of AtaiBeckley in September 2026, adding clinical-stage assets for treatment-resistant depression. Revenue reached $23.0 billion in Q2 2026, up 48% year over year, prompting an upward revision to full-year guidance. Analysts maintain a consensus Strong Buy rating with average price targets implying further upside.
PFE Overview and Recent Performance
Pfizer Inc. focuses on oncology, vaccines, internal medicine, and rare diseases, with a large established product base. In recent market activity, PFE shares traded near $27.72, posting a one-month gain of 5% and a one-year advance of 19%. Q2 2026 revenue totaled $15.03 billion, up 3% year over year, supported by 5% operational growth in non-COVID products. The company raised its 2026 revenue guidance midpoint to $61.5 billion and expanded cost-saving initiatives. Oncology and newly launched or acquired assets continued to show double-digit growth. Wall Street consensus reflects a Moderate Buy rating with modest upside to average price targets.
Trending AI Robots
Tickeron maintains a curated Trending AI Robots section that highlights the strongest performing AI trading bots from its extensive library. The platform offers hundreds of AI Trading Bots that trade thousands of different tickers across equities, ETFs, and other instruments. Only those demonstrating consistent results under prevailing market conditions appear in the trending section. Available bots encompass a wide range of trading styles, strategies, timeframes, performance metrics, and ticker universes. Users can review detailed statistics including win rates, drawdowns, and trade frequency before selecting bots aligned with their objectives. Explore the full selection on the Trending AI Robots page.
Head-to-Head Comparison
LLY operates with a concentrated growth model centered on high-demand GLP-1 therapies, delivering superior revenue expansion and market capitalization above $1 trillion. PFE maintains a broader, diversified portfolio with emphasis on oncology and established brands, resulting in steadier but slower top-line trends and a market capitalization near $158 billion. Recent momentum favors LLY on absolute returns, while PFE exhibits lower volatility and a substantially higher dividend yield. Risk factors differ: LLY faces competition and valuation sensitivity in the obesity space, whereas PFE contends with patent expirations and post-COVID normalization. Sector exposure overlaps in pharmaceuticals, yet LLY shows greater sensitivity to metabolic health trends and PFE to broader biopharma recovery.
Tickeron AI Verdict
Based on observable factors such as revenue trajectory, trend consistency in key therapeutic areas, and recent catalysts including acquisitions and guidance revisions, Tickeron’s AI models currently assign a higher probabilistic weighting to LLY for growth-oriented positioning. PFE registers as a more stable alternative with attractive income characteristics. Outcomes remain subject to evolving market conditions, regulatory developments, and competitive dynamics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LLY is a Hold and PFE is a Hold.
| LLY | PFE | LLY / PFE | |
| Capitalization | 1.03T | 158B | 651% |
| EBITDA | 41.7B | 13.5B | 309% |
| Gain YTD | 7.799 | 16.818 | 46% |
| P/E Ratio | 38.70 | 36.39 | 106% |
| Revenue | 79.7B | 63.7B | 125% |
| Total Cash | 8.95B | 11.7B | 76% |
| Total Debt | 54.9B | 63.2B | 87% |
LLY | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 80 | 94 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 50 Fair valued | 17 Undervalued | |
PROFIT vs RISK RATING 1..100 | 11 | 100 | |
SMR RATING 1..100 | 14 | 83 | |
PRICE GROWTH RATING 1..100 | 44 | 46 | |
P/E GROWTH RATING 1..100 | 69 | 5 | |
SEASONALITY SCORE 1..100 | 50 | 41 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (17) in the Pharmaceuticals Major industry is somewhat better than the same rating for LLY (50). This means that PFE’s stock grew somewhat faster than LLY’s over the last 12 months.
LLY's Profit vs Risk Rating (11) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (100). This means that LLY’s stock grew significantly faster than PFE’s over the last 12 months.
LLY's SMR Rating (14) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (83). This means that LLY’s stock grew significantly faster than PFE’s over the last 12 months.
LLY's Price Growth Rating (44) in the Pharmaceuticals Major industry is in the same range as PFE (46). This means that LLY’s stock grew similarly to PFE’s over the last 12 months.
PFE's P/E Growth Rating (5) in the Pharmaceuticals Major industry is somewhat better than the same rating for LLY (69). This means that PFE’s stock grew somewhat faster than LLY’s over the last 12 months.
| LLY | PFE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 83% | 2 days ago 54% |
| Stochastic ODDS (%) | 2 days ago 75% | 2 days ago 49% |
| Momentum ODDS (%) | 2 days ago 56% | 2 days ago 59% |
| MACD ODDS (%) | 2 days ago 44% | 2 days ago 63% |
| TrendWeek ODDS (%) | 2 days ago 70% | 2 days ago 56% |
| TrendMonth ODDS (%) | 2 days ago 58% | 2 days ago 50% |
| Advances ODDS (%) | 2 days ago 70% | 2 days ago 54% |
| Declines ODDS (%) | 9 days ago 54% | 4 days ago 56% |
| BollingerBands ODDS (%) | 2 days ago 61% | 2 days ago 53% |
| Aroon ODDS (%) | 2 days ago 62% | 2 days ago 51% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LLY’s FA Score shows that 2 FA rating(s) are green while PFE’s FA Score has 2 green FA rating(s).
- LLY’s FA Score: 2 green, 3 red.
- PFE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LLY’s TA Score shows that 3 TA indicator(s) are bullish while PFE’s TA Score has 4 bullish TA indicator(s).
- LLY’s TA Score: 3 bullish, 7 bearish.
- PFE’s TA Score: 4 bullish, 5 bearish.
Price Growth
LLY (@Pharmaceuticals: Major) experienced а +3.34% price change this week, while PFE (@Pharmaceuticals: Major) price change was -0.22% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.82%. For the same industry, the average monthly price growth was -6.21%, and the average quarterly price growth was +15.37%.
Reported Earning Dates
LLY is expected to report earnings on Oct 29, 2026.
PFE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.82% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| GSPCX | 12.85 | 0.02 | +0.16% |
| Goldman Sachs Large Cap Equity C | |||
| ISCCX | 34.25 | -0.07 | -0.20% |
| Federated Hermes Intl Small-Mid Co C | |||
| CFIOX | 17.80 | -0.10 | -0.56% |
| Cantor Fitzgerald International Eq A | |||
| FCVIX | 21.04 | -0.13 | -0.61% |
| Fidelity Advisor Small Cap Value I | |||
| ARIIX | 10.86 | -0.11 | -1.00% |
| AB Global Real Estate Investment II I | |||
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | +0.07% | ||
| BMY - PFE | 57% Loosely correlated | +0.35% | ||
| MRK - PFE | 55% Loosely correlated | -0.19% | ||
| AMGN - PFE | 53% Loosely correlated | +1.55% | ||
| BIIB - PFE | 51% Loosely correlated | -1.62% | ||
| GSK - PFE | 48% Loosely correlated | -1.65% | ||
More | ||||